Condition: Peroxisome Biogenesis Disorder · Zellweger Spectrum Disorder · RCDP - Rhizomelic Chondrodysplasia Punctata · Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
The Peroxisome Biogenesis Disorders (PBD) are a group of inherited disorders due to defects in peroxisome assembly causing complex developmental and metabolic sequelae. In spite of advancements in peroxisome biology, the pathophysiology remains unknown, the spectrum of phenotypes poorly characterized and the natural history not yet systematically reported. Our aims are to further define this population clinically, biochemically and genetically. The investigators will prospectively follow patients from Canada, the US and internationally, and collect data from medical evaluations, blood, urine and imaging studies that would be performed on a clinical care basis. For patients who are unable to attend our clinic, we will collect all medical records and images since birth as well as subsequent records/images for the next 5 years or until the end of the study. Clinical data from medical records will be banked in our Peroxisomal Disorder Research Databank and Biobank. The investigators will use this information to identify standards of care and improve management.
This description comes directly from the study's public registry record.
Nancy E Braverman, MD, MS · (1) 514-934-1934 · nancy.braverman@mcgill.ca
Evelyn M Zavacky, MSc · (1) 514-934-1934 · pbd.genetics@mcgill.ca
Always discuss trial participation with your own doctor first.
| Research Institute of the McGill University Health Center | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01668186